FIG 4.

Patient-reported convenience of the subcutaneous injection and intravenous infusion. Item 6 of the modified TASQ asked, “How convenient is it for you to have your [IV infusion/SC injection]?” The modified TASQ was completed by patients after treatment administration in cycle-1 (baseline), cycle-3, and at EOT. EOT data could have been collected after administration of the last dose. ^aC1D2 for patients who received IV amivantamab because of split dosing. C, cycle; D, day; EOT, end of treatment; IV, intravenous; SC, subcutaneous; TASQ, Therapy Administration Satisfaction Questionnaire.